NASDAQ:OVID

Ovid Therapeutics Stock Forecast, Price & News

$3.37
-0.08 (-2.32 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.37
$3.51
50-Day Range
$3.37
$4.04
52-Week Range
$2.25
$4.80
Volume527,906 shs
Average Volume1.85 million shs
Market Capitalization$228.93 million
P/E Ratio2.01
Dividend YieldN/A
Beta1.79
30 days | 90 days | 365 days | Advanced Chart
Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Ovid Therapeutics logo

About Ovid Therapeutics

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

216th out of 1,351 stocks

Pharmaceutical Preparations Industry

103rd out of 664 stocks

Analyst Opinion: 3.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

Is Ovid Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ovid Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View analyst ratings for Ovid Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Ovid Therapeutics?

Wall Street analysts have given Ovid Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Ovid Therapeutics
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Monday, August, 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.07.
View Ovid Therapeutics' earnings history
.

How has Ovid Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OVID stock has increased by 25.7% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OVID?

8 analysts have issued 12 month target prices for Ovid Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they expect Ovid Therapeutics' stock price to reach $10.83 in the next twelve months. This suggests a possible upside of 221.5% from the stock's current price.
View analysts' price targets for Ovid Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Jeremy Max Levin, Chairman & Chief Executive Officer
  • Amit Rakhit, President & Chief Medical Officer
  • Jason Tardio, Chief Operating Officer
  • Jeffrey A. Rona, Chief Financial, Accounting & Business Officer
  • Claude Nicaise, Head-Research & Development

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.78%), Vanguard Group Inc. (5.17%), BlackRock Inc. (1.77%), Globeflex Capital L P (1.49%), Millennium Management LLC (1.13%) and Wells Fargo & Company MN (0.67%). Company insiders that own Ovid Therapeutics stock include Amit Rakhit, Jeremy M Levin and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics
.

Which institutional investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Goldman Sachs Group Inc., Northern Trust Corp, Geode Capital Management LLC, Susquehanna International Group LLP, Charles Schwab Investment Management Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Ovid Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Ovid Therapeutics stock?

OVID stock was purchased by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Millennium Management LLC, BVF Inc. IL, Ergoteles LLC, AQR Capital Management LLC, Morgan Stanley, Morgan Stanley, and Sei Investments Co.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Jeremy M Levin, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $3.37.

How much money does Ovid Therapeutics make?

Ovid Therapeutics has a market capitalization of $228.93 million and generates $12.62 million in revenue each year. The company earns $-81,040,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 67 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

Where are Ovid Therapeutics' headquarters?

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at (646) 661-7661 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.